SRNE
Income statement / Annual
Last year (2022), Sorrento Therapeutics, Inc.'s total revenue was $62.84 M,
an increase of 18.78% from the previous year.
In 2022, Sorrento Therapeutics, Inc.'s net income was -$572.84 M.
See Sorrento Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$62.84 M |
$52.90 M |
$39.99 M |
$31.43 M |
$21.19 M |
$151.86 M |
$8.15 M |
$4.59 M |
$3.83 M |
$460,148.00 |
| Cost of Revenue |
$33.45 M
|
$13.03 M
|
$9.94 M
|
$12.24 M
|
$10.07 M
|
$11.03 M
|
$3.70 M
|
$1.95 M
|
$2.04 M
|
$4,440.00
|
| Gross Profit |
$29.39 M
|
$39.87 M
|
$30.05 M
|
$19.20 M
|
$11.12 M
|
$140.83 M
|
$4.46 M
|
$2.64 M
|
$1.78 M
|
$455,708.00
|
| Gross Profit Ratio |
0.47
|
0.75
|
0.75
|
0.61
|
0.52
|
0.93
|
0.55
|
0.58
|
0.47
|
0.99
|
| Research and Development Expenses |
$221.23 M
|
$206.92 M
|
$111.34 M
|
$106.88 M
|
$76.96 M
|
$55.53 M
|
$42.18 M
|
$31.34 M
|
$23.98 M
|
$9.02 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$63.64 M
|
$38.33 M
|
$24.22 M
|
$20.13 M
|
$9.99 M
|
$6.32 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$5.37 M
|
-$2.04 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$182.34 M
|
$196.86 M
|
$116.18 M
|
$103.56 M
|
$63.64 M
|
$32.96 M
|
$22.18 M
|
$20.13 M
|
$9.99 M
|
$6.32 M
|
| Other Expenses |
$130.14 M
|
$4.14 M
|
$4.05 M
|
$3.94 M
|
$3.01 M
|
$2.61 M
|
$845,000.00
|
$1.16 M
|
$2.35 M
|
$804,070.00
|
| Operating Expenses |
$533.70 M
|
$407.92 M
|
$231.57 M
|
$214.38 M
|
$140.60 M
|
$88.49 M
|
$64.35 M
|
$52.63 M
|
$36.32 M
|
$16.14 M
|
| Cost And Expenses |
$567.15 M
|
$420.95 M
|
$241.51 M
|
$226.61 M
|
$150.67 M
|
$99.52 M
|
$68.05 M
|
$54.58 M
|
$38.36 M
|
$16.14 M
|
| Interest Income |
$0.00
|
$0.00
|
$24,000.00
|
$1.09 M
|
$921,000.00
|
$241,000.00
|
$272,000.00
|
$24,000.00
|
$12,000.00
|
$9,615.00
|
| Interest Expense |
$8.57 M
|
$10.22 M
|
$20.18 M
|
$36.14 M
|
$57.63 M
|
$4.98 M
|
$1.61 M
|
$1.65 M
|
$1.63 M
|
$253,194.00
|
| Depreciation & Amortization |
$13.25 M
|
$16.32 M
|
$14.71 M
|
$15.04 M
|
$9.05 M
|
$7.08 M
|
$2.89 M
|
$2.37 M
|
$3.18 M
|
$1.29 M
|
| EBITDA |
-$539.93 M |
-$435.99 M |
-$275.69 M |
-$308.40 M |
-$147.10 M |
$27.38 M |
-$60.34 M |
-$9.74 M |
-$31.55 M |
-$20.37 M |
| EBITDA Ratio |
-8.59
|
-7.25
|
-4.8
|
-5.83
|
-5.68
|
0.39
|
-6.99
|
-1.19
|
-8.25
|
-44.26
|
| Operating Income Ratio |
-8.03
|
-6.96
|
-5.04
|
-6.21
|
-6.11
|
0.34
|
-7.35
|
-16.12
|
-9.08
|
-47.09
|
| Total Other Income/Expenses Net |
-$57.43 M
|
-$94.48 M
|
-$66.06 M
|
-$100.18 M
|
-$63.36 M
|
-$10.02 M
|
-$4.94 M
|
$36.23 M
|
-$1.62 M
|
-$6.23 M
|
| Income Before Tax |
-$561.75 M
|
-$462.53 M
|
-$310.58 M
|
-$359.58 M
|
-$213.78 M
|
$15.32 M
|
-$64.83 M
|
-$13.76 M
|
-$36.36 M
|
-$21.91 M
|
| Income Before Tax Ratio |
-8.94
|
-8.74
|
-7.77
|
-11.44
|
-10.09
|
0.1
|
-7.95
|
-3
|
-9.51
|
-47.62
|
| Income Tax Expense |
-$2.42 M
|
-$33.52 M
|
-$2.01 M
|
-$473,000.00
|
-$6.27 M
|
-$36.04 M
|
-$896,000.00
|
$36.31 M
|
-$1.70 M
|
$9,615.00
|
| Net Income |
-$572.84 M
|
-$429.01 M
|
-$308.57 M
|
-$359.10 M
|
-$203.54 M
|
$9.06 M
|
-$60.92 M
|
-$45.81 M
|
-$34.66 M
|
-$21.91 M
|
| Net Income Ratio |
-9.12
|
-8.11
|
-7.72
|
-11.42
|
-9.6
|
0.06
|
-7.47
|
-9.98
|
-9.06
|
-47.62
|
| EPS |
-1.37 |
-1.46 |
-1.34 |
-2.56 |
-1.92 |
0.13 |
-1.21 |
-1.24 |
-1.3 |
-1.46 |
| EPS Diluted |
-1.37 |
-1.46 |
-1.34 |
-2.56 |
-1.92 |
0.13 |
-1.21 |
-1.24 |
-1.3 |
-1.46 |
| Weighted Average Shares Out |
$419.32 M
|
$294.77 M
|
$229.82 M
|
$140.51 M
|
$106.15 M
|
$69.74 M
|
$50.36 M
|
$36.91 M
|
$26.68 M
|
$15.05 M
|
| Weighted Average Shares Out Diluted |
$419.32 M
|
$294.77 M
|
$229.82 M
|
$140.51 M
|
$106.15 M
|
$70.38 M
|
$50.36 M
|
$36.91 M
|
$26.68 M
|
$15.05 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
